ReachMD

Episodes 16-29 of 29

• 

  MinuteCE®

  Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma

  • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  0.75 credits 4 episodes

• 

  MinuteCE®

  Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma

  • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  0.75 credits 4 episodes

• 

  RestartResume

  Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

  MinuteCE®

  Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Omid Hamid, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma

  MinuteCE®

  Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma

  • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  0.75 program credits

• 

  RestartResume

  Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma

  MinuteCE®

  Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Omid Hamid, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

  MinuteCE®

  Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Omid Hamid, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  MinuteCE®

  Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  0.75 program credits

• 

  RestartResume

  Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma

  MinuteCE®

  Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  0.75 program credits

• 

  RestartResume

  Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  MinuteCE®

  Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  MinuteCE®

  Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  0.75 program credits

• 

  RestartResume

  Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes

  CME/CE

  Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes

  • 

    

    Thilo Krüger, MD, PhD

    Peer

  • 

    

    Steven Fishbane, MD

    Peer

  • 

    

    Lucio Manenti, MD, PhD

    Peer

  0.50 credits

• 

  RestartResume

  KALMing the Itch: Improving QoL in Patients with CKD-aP 

  CME/CE

  KALMing the Itch: Improving QoL in Patients with CKD-aP 

  • 

    

    Joel Topf, MD

    Peer

  • 

    

    Kieran McCafferty, MD

    Peer

  0.25 credits

• 

  RestartResume

  Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma 

  CME/CE

  Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma 

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Tara C. Mitchell, MD

    Peer

  0.25 credits

• 

  RestartResume

  Separating Fact from Fiction: The Realities of CKD-aP

  CME/CE

  Separating Fact from Fiction: The Realities of CKD-aP

  • 

    

    Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS

    Peer

  • 

    

    Antoine Lanot, MD, PhD

    Peer

  0.25 credits

• Prev
• 1
• 2